Successful experience in the use of teduglutide in children with short bowel syndrome

The article presents an overview of current trends in the approach to the treatment of patients with short bowel syndrome (SBS), including the example of pediatric patients in the Tyumen region. SBC is an extremely rare nosological form in the practice of a clinician and, as a rule, patients with such a diagnosis require a multidisciplinary approach. The most common manifestations of the disease are symptoms of malabsorption: dumping syndrome, progressive weight loss, deficiency of macro- and micronutrients, other manifestations of dyspepsia and abdominal pain. Attention is drawn to the fact that the number and intensity of symptoms varies significantly among patients. The traditional tactic for treating such patients includes the need for lifelong parenteral nutrition or, as a necessary measure, intestinal transplantation. Rehabilitation measures in SBS children should take into account the requirements for correcting impaired absorption and restoring normal trophic status; relief of diarrhea, prevention and treatment of dysbiosis; control and correction of general digestive disorders. We found that the analogue of glucagon-like peptide 2 (GLP-2) — teduglutide — makes it possible to reduce the amount of parenteral nutrition, infusion time, and also achieve a complete transition to enteral autonomy. The method of treatment with Teduglutide is the most promising for patients of this category.

Contribution:
Tropina E.P., Zmanovskaya V.A. — concept and design of the study;
Tropina E.P. — collection and processing of the material;
Zmanovskaya V.A. — statistical processing;
Tropina E.P. — writing the text;
Zmanovskaya V.A. — edi­ting.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: September 12, 2022
Accepted: September 20, 2022
Published: October 31, 2022

1. Cohran V.C., Prozialeck J.D., Cole C.R. Redefining short bowel syndrome in the 21st century. Pediatr Res. 2017; 81(4): 540–9. https://doi.org/10.1038/pr.2016.265

2. Mutanen A., Wales P.W. Etiology and prognosis of pediatric short bowel syndrome. Semin Pediatr Surg. 2018; 27(4): 209–17. https://doi.org/10.1053/j.sempedsurg.2018.07.009

3. Engelstad H.J., Danko M.E. Short bowel syndrome in an infant. Neoreviews. 2020; 21(6): 370–82. https://doi.org/10.1542/neo.21-6-e370

4. Massironi S., Cavalcoli F., Rausa E., Invernizzi P., Braga M., Vecchi M. Understanding short bowel syndrome: Current status and future perspectives. Dig Liver Dis. 2020; 52(3): 253–61. https://doi.org/10.1016/j.dld.2019.11.013

5. Fuglestad M.A., Thompson J.S. Inflammatory bowel disease and short bowel syndrome. Surg Clin North Am. 2019; 99(6): 1209–21. https://doi.org/10.1016/j.suc.2019.08.010

6. Carroll R.E., Benedetti E., Schowalter J.P., Buchman A.L. Management and complications of short bowel syndrome: an updated review. Curr Gastroenterol Rep. 2016; 18(7): 40. https://doi.org/10.1007/s11894-016-0511-3

7. Sun H., Eliasson J., Fuglsang K.A., Hvistendahl M., Naimi R.M., Jeppesen P.B. Repeated metabolic balance studies in patients with short bowel syndrome. J Parenter Enteral Nutr. 2020; 44(4): 677–87. https://doi.org/10.1002/jpen.1704

8. Muff J.L., Sokolovski F., Walsh-Korb Z., Choudhury R.A., Dunn J.C.Y., Holland-Cunz S.G., et al. Surgical treatment of short bowel syndrome-the past, the present and the future, a descriptive review of the literature. Children (Basel). 2022; 9(7): 1024. https://doi.org/10.3390/children9071024

9. Huang Y., Guo F., Li Y., Wang J., Li J. Fecal microbiota signatures of adult patients with different types of short bowel syndrome. J Gastroenterol Hepatol. 2017; 32(12): 1949–57. https://doi.org/10.1111/jgh.13806

10. Piper H.G. Intestinal microbiota in short bowel syndrome. Semin Pediatr Surg. 2018; 27(4): 223–8. https://doi.org/10.1053/j.sempedsurg.2018.07.007

11. Piper H.G., Coughlin L.A., Hussain S., Nguyen V., Channabasappa N., Koh A.Y. The impact of lactobacillus probiotics on the gut microbiota in children with short bowel syndrome. J Surg Res. 2020; 251: 112–8. https://doi.org/10.1016/j.jss.2020.01.024

12. Christian V.J., Van Hoorn M., Walia CL.S., Silverman A., Goday P.S. Pediatric feeding disorder in children with short bowel syndrome. J Pediatr Gastroenterol Nutr. 2021; 72(3): 442–5. https://doi.org/10.1097/MPG.0000000000002961

13. Sowerbutts A.M., Panter C., Dickie G., Bennett B., Ablett J., Burden S., Lal S. Short bowel syndrome and the impact on patients and their families: a qualitative study. J Hum Nutr Diet. 2020; 33(6): 767–74. https://doi.org/10.1111/jhn.12803

14. Billiauws L., Thomas M., Le Beyec-Le Bihan J., Joly F. Intestinal adaptation in short bowel syndrome. What is new? Nutr Hosp. 2018; 35(3): 731–7. https://doi.org/10.20960/nh.1952

15. Merras-Salmio L., Pakarinen M.P. Infection prevention and management in pediatric short bowel syndrome. Front Pediatr. 2022; 10: 864397. https://doi.org/10.3389/fped.2022.864397

16. Raghu V.K., Binion D.G., Smith K.J. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. Am J Clin Nutr. 2020; 111(1): 141–8. https://doi.org/10.1093/ajcn/nqz269

17. Diamanti A., Conforti A., Panetta F., Torre G., Candusso M., Bagolan P., et al. Long-term outcome of home parenteral nutrition in patients with ultra-short bowel syndrome. J Pediatr Gastroenterol Nutr. 2014; 58(4): 438–42. https://doi.org/10.1097/MPG.0000000000000242

18. Austin K., Bonnes S., Daniel H. Controversy in nutrition recommendations for short bowel syndrome: how type of SBS impacts response. Curr Gastroenterol Rep. 2019; 21(12): 64. https://doi.org/10.1007/s11894-019-0731-4

19. Naimi R.M., Hvistendahl M., Nerup N., Ambrus R., Achiam M.P., Svendsen L.B., et al. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine. 2019; 46: 444–51. https://doi.org/10.1016/j.ebiom.2019.07.016

20. Pironi L., Sasdelli A.S., Venerito F.M., Musio A., Pazzeschi C., Guidetti M. Candidacy of adult patients with short bowel syndrome for treatment with glucagon-like peptide-2 analogues: A systematic analysis of a single centre cohort. Clin Nutr. 2021; 40(6): 4065–74. https://doi.org/10.1016/j.clnu.2021.02.011

21. Kochar B., Herfarth H.H. Teduglutide for the treatment of short bowel syndrome - a safety evaluation. Expert Opin Drug Saf. 2018; 17(7): 733–9. https://doi.org/10.1080/14740338.2018.1483332

22. Seidner D.L., Fujioka K., Boullata J.I., Iyer K., Lee H.M., Ziegler T.R. Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: STEPS-3 study. Nutr Clin Pract. 2018; 33(4): 520–7. https://doi.org/10.1002/ncp.10092

23. Choudhury R.A., Yoeli D., Hoeltzel G., Moore H.B., Prins K., Kovler M. et al. STEP improves long-term survival for pediatric short bowel syndrome patients: A Markov decision analysis. J Pediatr Surg. 2020; 55(9): 1802–8. https://doi.org/10.1016/j.jpedsurg.2020.03.017

24. Harpain F., Schlager L., Hütterer E., Dawoud C., Kirchnawy S., Stift J., et al. Teduglutide in short bowel syndrome patients: A way back to normal life? JPEN J Parenter Enteral Nutr. 2022; 46(2): 300–9. https://doi.org/10.1002/jpen.2272

25. Kocoshis S.A., Merritt R.J., Hill S., Protheroe S., Carter B.A., Horslen S. et al. Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, Phase III study. JPEN J Parenter Enteral Nutr. 2020; 44(4): 621–31. https://doi.org/10.1002/jpen.1690

26. Iyer K.R., Kunecki M., Boullata J.I., Fujioka K., Joly F., Gabe S., et al. Independence from parenteral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2017; 41(6): 946–51. https://doi.org/10.1177/0148607116680791

27. McKeage K. Teduglutide: a guide to its use in short bowel syndrome. Clin Drug Investig. 2015; 35(5): 335–40. https://doi.org/10.1007/s40261-015-0286-6

28. Proli F., Faragalli A., Talbotec C., Bucci A., Zemrani B., Chardot C., et al. Variation of plasma citrulline as a predictive factor for weaning off long-term parenteral nutrition in children with neonatal short bowel syndrome. Clin Nutr. 2021; 40(8): 4941-7. https://doi.org/10.1016/j.clnu.2021.07.017

29. Vecino López R., Andrés Moreno A.M., Ramos Boluda E., Martinez-Ojinaga Nodal E., Hernanz Macías A., Prieto Bozano G., et al. Plasma citrulline concentration as a biomarker of intestinal function in short bowel syndrome and in intestinal transplant. An Pediatr (Barc). 2013; 79(4): 218–23. https://doi.org/10.1016/j.anpedi.2013.02.007

30. Diamanti A., Panetta F., Gandullia P., Morini F., Noto C., Torre G., et al. Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome. Langenbecks Arch Surg. 2011; 396(7): 1041-6. https://doi.org/10.1007/s00423-011-0813-8

31. Sahin P., Molnár A., Varga M., Bíró I., Kőmíves C., Fejér C., et al. Clinical nutrition therapy in patients with short bowel syndrome in line with principles of personalized medicine. Orv Hetil. 2014; 155(51): 2054-62. https://doi.org/10.1556/OH.2014.29973

32. Kounatidis D., Vallianou N.G., Tsilingiris D., Christodoulatos G.S., Geladari E., Stratigou T., et al. Therapeutic potential of GLP-2 analogs in gastrointestinal disorders: current knowledge, nutritional aspects, and future perspectives. Curr Nutr Rep. 2022. https://doi.org/10.1007/s13668-022-00433-0

33. Norsa L., Lambe C., Abboud S.A., Barbot-Trystram L., Ferrari A., Talbotec C., et al. The colon as an energy salvage organ for children with short bowel syndrome. Am J Clin Nutr. 2019; 109(4): 1112–8. https://doi.org/10.1093/ajcn/nqy367

34. Jeppesen P.B., Gabe S.M., Seidner D.L., Lee H.M., Olivier C. Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology. 2018; 154(4): 874–85. https://doi.org/10.1053/j.gastro.2017.11.023

35. Walker A.A., Cole C.R. Ultra-short bowel syndrome during infancy: improving outcomes and novel therapies. Curr Opin Pediatr. 2019; 31(2): 177–81. https://doi.org/10.1097/MOP.0000000000000738